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Abstract
Background: Plantar fasciopathy is a common cause of foot pain, accounting for 11 to 15 % of all foot symptoms
requiring professional care in adults. Although many patients have complete resolution of symptoms within
12 months, many patients wish to reduce this period as much as possible. Orthotic devices are a frequently applied
option of treatment in daily practice, despite a lack of evidence on the effectiveness. Therefore, the objective is to
study the (cost)-effectiveness of custom made insoles by a podiatrist, compared to placebo insoles and usual care
in patients with plantar fasciopathy in general practice and sports medicine clinics.
Method/design: This study is a multi-center three-armed participant and assessor-blinded randomized controlled
trial with 6-months follow-up. Patients with plantar fasciopathy, with a minimum duration of complaints of 2 weeks
and aged between 18 and 65, who visit their general practitioner or sport physician are eligible for inclusion. A
total of 185 patients will be randomized into three parallel groups. One group will receive usual care by the general
practitioner or sports physician alone, one group will be referred to a podiatrist and will receive a custom made
insole, and one group will be referred to a podiatrist and will receive a placebo insole. The primary outcome will be
the change from baseline to 12 weeks follow-up in pain severity at rest and during activity on a 0–10 numerical
rating scale (NRS). Secondary outcomes include foot function (according to the Foot Function Index) at 6, 12 and
26 weeks, recovery (7-point Likert) at 6, 12 and 26 weeks, pain at rest and during activity (NRS) at 6 and 26 weeks
and cost-effectiveness of the intervention at 26-weeks. Measurements will take place at baseline and at, 2, 4, 6, 12
and 26 weeks of follow-up.
Discussion: The treatment of plantar fasciopathy is a challenge for health care professionals. Orthotic devices are
frequently applied, despite a lack of evidence of the effectiveness on patient reported outcome. The results of this
randomized controlled trial will improve the evidence base for treating this troublesome condition in daily practice.
Trial registration: Dutch Trial Registration:NTR5346. Date of registration: August 5th 2015.
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Background
Plantar fasciopathy is a common cause of foot pain in
both primary and secondary care. Plantar fasciopathy
was formerly known as plantar fasciitis in literature. It
typically affects middle aged or older women (40–60
years), with being overweight as a risk factor [1–3].
Besides this, plantar fasciopathy is also commonly seen
in highly physically active people; plantar fasciopathy ac-
counts for 8–10 % of all running related injuries [4].
Plantar fasciopathy accounts for approximately 11 to
15 % of all foot symptoms requiring professional care
among adults and it has been estimated that a general
practitioner (GP), with an average size practice, diagno-
ses around eight new patients each year [5, 6].
The etiology of plantar fasciopathy is poorly under-
stood and is probably multifactorial [7, 8]. Histopath-
ology studies have indicated that fasciopathy of the
plantar fascia might be a possible cause of pain [9, 10].
Repetitive microtrauma and inflammation have been
suggested as possible etiologic mechanisms, however
these conclusions are mostly based on clinical experi-
ence and there is little evidence from research [11–13].
Plantar fasciopathy is characterized by pain over the
anteromedial aspect of the inferior heel and the pain
tends to increase after periods of inactivity or during
weight bearing activities. The diagnosis can be made pri-
marily based on symptoms and physical examination [7].
Patients often report low quality of life and reduced
participation as their heel pain prevents them from per-
forming simple every day activities [14, 15]. The clinical
course of plantar fasciopathy is considered favorable as
80 % of patients will have a complete resolution of
symptoms within 12 months [7]. Despite the favorable
clinical course on the long term, many patients do ex-
pect and hope for short term pain relief and often mul-
tiple treatments are applied during the course of their
complaints [7, 16].
The most commonly prescribed treatments include
footwear modification, taping, stretching exercises, anti-
inflammatory agents, Extra Corporal shock wave therapy
(ESWT) and cortisone injections [7, 12]. Reviews con-
clude that most of these treatments have a role in the
management of plantar fasciopathy although at different
time points in the clinical course [7, 11–13, 17]. Despite
the use of many different treatment strategies in plantar
fasciopathy, there is insufficient evidence for the effect-
iveness of these treatments provided by high quality ran-
domized controlled trials [12, 13, 18, 19].
It has therefore been suggested that treatment options
should be offered to the patient in sequence, either
based on objective patient criteria or based on the
preference of the patient [12]. Different combinations of
conservative treatments successfully manage 85–90 % of
the cases of plantar fasciopathy [16]. Orthotic devices
seem to be a frequently applied treatment option,
despite a lack of evidence on the effectiveness [6, 16].
A clinical practice guideline from the American College of
Foot and Ankle Surgeons recommends anti-inflammatory
drugs (NSAIDs), stretching and prefabricated orthotics as
the initial steps in the conservative treatment of plantar
heel pain and prescription orthotic devices as a secondary
treatment option [6]. Orthotic devices include a low risk
intervention, they are relatively painless compared to
other treatments, such as shock wave therapy or cortisone
injections, and they have a working mechanism that influ-
ences on what are thought to be important biomechanical
factors in the etiology of plantar fasciopathy. There are
different theoretical models on the potential working
mechanism of orthotic devices [20]. The most common
theory is that orthotic devices optimize the biomechanical
loading of the foot, specifically to decrease excessive pro-
nation, to off-load the plantar fascia at its origin and to re-
create the heel pad [21].
Orthotic insoles (custom made by a podiatrist) and pre-
fabricated insoles belong to the most researched biomech-
anical treatments of plantar fasciopathy [12, 18, 19, 22].
However a Cochrane review on the effectiveness of insoles
on foot pain concludes that there is insufficient evidence
from high quality trials to support the effectiveness of or-
thotics in patients with plantar fasciopathy on different
outcome measures such as pain, function and recovery
[22]. Only one study included in this review compared the
effectiveness of a custom made insole to a prefabricated
insole (non-custom) and a sham insole (placebo) in pa-
tients with plantar fasciopathy. Both the custom-made
and prefabricated insoles had slightly better outcomes on
short term, but were not significantly different and both
did not have beneficial effects on pain at 12 months [18].
To our knowledge there is no literature available on
the cost-effectiveness of orthotic insoles for the treat-
ment of plantar fasciopathy.
Given the favorability of treatment of plantar fascio-
pathy with insoles, the high estimated costs involved
due to the custom-made nature and the insufficient
evidence for this intervention, there is a need to
conduct a high quality randomized controlled trial in-
vestigating the effectiveness of orthotic insoles on
pain, function and recovery in patients with plantar
fasciopathy.
Objectives
The primary objective of our study is to examine the ef-
fectiveness of custom made insoles by a podiatrist, com-
pared to placebo insoles and compared to usual care in
general practice and sports medicine alone in patients
with plantar fasciopathy in terms of pain.
The secondary objective of our study is to examine
the cost-effectiveness of custom made insoles by a
Rasenberg et al. BMC Musculoskeletal Disorders  (2016) 17:31 Page 2 of 8




The STAP-study is a multi-center three-armed armed
participant and assessor-blinded randomized controlled
trial with 6-months follow-up. STAP is an acronym for:
Soles as Treatment Against Pain in feet. The reporting
of the study protocol will follow CONSORT guidelines
[23]. The study design and flow of participants is shown
in Fig. 1. Participants will be recruited in general prac-
tice and sports medicine clinics, both accessible without
referral. Those who are eligible and give written consent
to participate will be randomly assigned to either the
usual care group, the placebo insole group and the
custom-made insole group. The study is funded by the
Netherlands Organization for Health Research and
Development (ZonMW) and the Dutch Association of
Podiatrists (NVvP). The study design, procedures and
informed consent procedure are in compliance with the
Declaration of Helsinki, 7th version, October 2013 [24].
The Medical Ethics Committee (number 2015–253) of
the Erasmus Medical Centre in Rotterdam has approved
this study. This permission includes the multi-centre
nature of this study, i.e. approval was given to recruit
patients at all sites.
Patient selection
Patients with plantar fasciopathy, characterized as pain
at the medial hind foot, presenting themselves to a GP
or sports physician, aged between 18 and 65 years and a
minimal pain duration of 2 weeks are eligible for
participation.
Participants will be excluded if they have recurrent
complaints of plantar fasciopathy for more than 2 years,
Fig. 1 STAP study Flow chart
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complaints caused by trauma, earlier treatment for
plantar fasciopathy by a podiatrist or treatment with or-
thotics, suspected (by the GP or sports physician)
(osteo)arthritis in the subtalar or talonavicular joint,
suspected tarsal tunnel syndrome, suspected stress frac-
tures, infections or tumors in the painful foot or pres-
ence of systemic diseases (such as Bechterew’s disease,
psoriasis or multiple sclerosis). Patients who have no
sufficient understanding of the Dutch language will also
be excluded, since they will not be able to complete the
questionnaires.
Sample size
Based on the RCT of Landorf et al. (2006) [18] –pain
score 63.4 (SD 21.5), with a difference in pain score of
10.5 (on a scale of 0–100) – it is estimated that with a
power of 80 % and an alpha of 0.05 (two-sided), it is
possible to detect an effect size of 0.5 with 10.5 points
difference on the pain score between patients with a pla-
cebo insole and custom made insole with 63 patients in
each study group. In addition, a larger difference is ex-
pected between the custom made insole group and the
usual care group. With a 12-point difference and identi-
cal means and SDs, a total of 44 patients are needed per
group. A Bonferroni correction will be performed for
the secondary comparisons to the usual care group.
Taking a loss to follow-up of 10 % into account, a total
of 185 patients with plantar fasciopathy (69 in custom
made group, 69 in placebo group and 47 in usual care
group) will be included in the trial.
Recruitment of study population
Recruitment of patients will take place in two different
settings. All eligible patients who consult a participating
GP or sports physician for plantar fasciopathy will be
considered for participation (prospective recruitment).
On average a GP will see 8 new patients each year. It is
estimated that 30 % of these patients will be willing to
participate. Therefore, a total of 47 participating GP’s
will be necessary to include 185 patients within two
years’ time. We aim for a minimum of 50 participating
GP’s or sports physicians.
All potentially eligible patients will be invited to par-
ticipate in the study and will receive comprehensive
information about the study. Patients that are willing to
participate will fill in a reply card with their contact de-
tails and send it to the research team. The research team
will then contact the interested patients and inform
them further about the study and check the inclusion
and exclusion criteria. If a patient is willing to participate
in the study and meets all inclusion criteria and none of
the exclusion criteria, he or she will sign the informed
consent form and send it to the research team. The
baseline questionnaire will subsequently be send to all
participating patients by email. After completing the
baseline questionnaire all patients will be randomized
into one of the three study groups.
Randomization procedure
After providing informed consent and baseline measure-
ment, randomization will be performed by an independ-
ent person with the use of a computer generated
randomization list using block randomization with ran-
dom block sizes between 3 and 10. This sequence is kept
hidden from all involved researchers. It can be expected,
that patients referred by a GP and patients referred by a
sports physician are different in terms of BMI and activ-
ity level. These have both been described as possible risk
factors for plantar fasciopathy and therefore might
influence treatment response [8]. For this reason the
randomization will be stratified for type of referral (GP
or sports physician). As a consequence patients from
both populations will be equally distributed across the
three treatment arms.
Interventions
Patients (n = 47) randomized to the usual care group will
receive an information booklet with general information
on plantar fasciopathy. This information booklet will
contain information on the use of pain medication and
possible stretching and strength exercises (plantar
specific stretching identical to the protocol used by
DiGiovanni et al. [25] and unilateral heel raises adapted
from exercises as described by Rathleff et al. [26]) that are
considered to be helpful for all patients with plantar fas-
ciopathy. The patients in this group will not be referred to
a podiatrist. They will receive usual care as provided by
their GP or sports physician.
Patients randomized to the custom made insole group
(n = 69) and the placebo insole group (n = 69) will a be
referred to a podiatrist. All patients that are referred to a
podiatrist will additionally receive the information book-
let identical to the usual care group as described above.
The first appointment with the podiatrist will take place
as soon as possible after randomization (preferably
within 1 week). All patients referred to a podiatrist will
receive a standardized intake with identical procedures.
These procedures have been discussed and agreed upon
with the participating podiatrists in a consensus meeting.
If a podiatrist could not attend they were given elaborate
explanation and the opportunity to give input during a
telephone conference.
The standardized intake at the podiatrist will consist
of an examination of the posture of the foot using the
standardized Foot Posture Index [27], the Hubscher test
[28], the navicular drop test [29] and the range of
motion in the tarsometarsal joint and the first meta-
tarsophalangeal joint (MTP-I) as measured with a
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goniometer. The podiatrists will report for each pa-
tient, whether they agree with the indication for
orthotic insoles as established by the GP or sports
physician. A 3D imprint of the feet of all patients
visiting a podiatrist will be made. All these examina-
tions will take place during the first appointment,
which will take approximately 50 min. During this
first appointment the podiatrist is blinded for the
outcome of the randomization. The podiatrist will be
informed about the allocated treatment, after the
first appointment.
All patients referred to a podiatrist will have a sec-
ond appointment within 2 weeks after the intake, of
approximately 10 min to pick up their insole. Patients
randomized to the custom made insole group will re-
ceive a custom made insole. Patients randomized to
the placebo insole group will receive a placebo insole
(Fig. 2), that has been custom designed for their foot
(based on a 3D imprint of their foot) without provid-
ing therapeutic effect, but still have the visual effect
of a podiatric insole. See Fig. 3 for the standardized
production procedure of the placebo insole. All pla-
cebo insoles will be produced by the same podiatrist
according to this protocol after receiving the 3D im-
print from the different podiatrists. The placebo
insoles will then be sent back to the different podia-
trists to give to the patients. The custom made insole
will always be patient tailored, but will be produced
according to usual podiatric care by the different po-
diatrists. A third checkup appointment will be offered
to the patients in the placebo insole group and the
custom made insole group after 12 weeks as part of
the usual podiatric care. Podiatrists with a practice
near participating GP’s and sports physicians were
approached to participate in the study. For every
participating GP or sports physician a nearby podia-
trist was found. In total 49 podiatrists have agreed to
participate in this study.
The use of co-intervention
In the 6 months of follow-up the GP’s and sports physi-
cians will provide their usual treatment to the patients.
They are discouraged from referring patients in the
usual care group to the podiatrist during follow-up.
Patients who receive co-interventions, will not count as
a failure in the analysis. The podiatrists will be allowed
to give advice on shoes and exercises as part of the podi-
atric intervention. Patients will report co-interventions
in the questionnaires.
Study outcomes
The primary outcome will be the change from baseline
to 12 weeks follow-up in pain severity at rest and during
activity on a 0–10 numerical rating scale (NRS). Second-
ary outcome measures include foot function as mea-
sured by the Foot Function Index at 6, 12 and 26 weeks
follow-up, perceived recovery measured on a 7-point
Fig. 2 The placebo insole
Fig. 3 The procedure for producing the placebo insole
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Likert scale (ranging from “worse than ever” to “com-
pletely recovered”, those who rate themselves as “slightly
recovered” to “worse than ever” will be deemed not re-
covered) at 6, 12 and 26 weeks follow-up, pain at rest
and during activity at 6 and 26 weeks follow-up and
cost-effectiveness of the intervention at 26-weeks follow-
up.
Measurements
During a 6 month follow-up the participating patients
will be asked to complete a total of six questionnaires.
At baseline, at 2 weeks, at 4 weeks, at 6 weeks, at
12 weeks and at 26 weeks of follow-up. The participants
will receive an e-mail that contains a secured hyperlink
to the questionnaire, using the survey application Lime
Survey. Phone calls and reminder emails will be used to
minimize loss to follow-up and missing data.
Baseline measurement
The baseline questionnaire will include questions on
demographics (age, gender, BMI, education level, work
and comorbidities), duration of pain, work activity
(type, magnitude and load), sports activities (including
the validated questionnaires SQUASH and Tegner)
[30, 31], general health (SF12) [32], quality of life
(EuroQol 5 dimensions) [33], neuropathic pain (DN4)
[34], function (Foot Function Index (FFI)) [35], dis-
ability (Manchester-Foot Pain and Disability Index
questionnaire (MPDI) [36], pain at rest and during
activity (11-point NRS-scale) [37], incidence of falling,
type of shoes and previously received medical care.
Follow-up measurements
The 2, 4 and 6 week questionnaires will include ques-
tions on recovery on a 7-point Likert scale [38], pain at
rest and during activity (NRS) and foot function (FFI).
The questionnaires at 12 and 26 weeks will include these
questions as well and will additionally include questions
on general health (SF12), quality of life (EuroQol), direct
cost (medical costs: health care visits, medication, med-
ical devices), indirect cost (absence from work, inability
to work) and current activity level. The patients random-
ized to the two podiatrist groups will also complete
questions on patient satisfaction and compliance to
treatment in the questionnaires at 12 and 26 weeks. In
the 26 week questionnaire we will additionally ask all
patients allocated to podiatric treatment to report their
expectation regarding the type of insole they received, in
order to assess the successfulness of blinding.
Data analysis
Differences between the intervention groups will be ana-
lyzed following the intention-to-treat principle. Linear
regression techniques for repeated measurements will be
used to compare pain severity between the intervention
group and control groups, which take the correlation of
multiple measurements within one patient into account.
A Bonferroni correction will be performed for the sec-
ondary comparisons to the usual care group. The ana-
lysis will be adjusted for potential confounders (at least
including age, gender, BMI and activity level).
Recovery, pain scores and function will be analyzed
using regression techniques for repeated measures using
generalized mixed models.
Mean direct, indirect and total costs will be estimated
and compared between the three study groups. Because
costs will not be normally distributed, 95 % confidence
intervals for the differences in mean costs will be ob-
tained by bias corrected and accelerated bootstrapping
(2000 replications). Differences in costs and differences
in recovery will be included in a cost-effectiveness ratio,
which estimates the additional costs to completely re-
cover one patient.
Confidence intervals for the cost-effectiveness ratio
will be calculated with bootstrapping, using the bias-
corrected percentile method with 5000 replications. An
incremental cost-effectiveness ratio will be estimated of
the incremental costs to recover one patient. Uncertainty
of this ratio will be evaluated by presenting a cost-
effectiveness plane and sensitivity analyses will be
performed to check the robustness of the results. An ac-
ceptability curve will also be presented.
Pre-defined subgroup analysis will be performed in pa-
tients with a long (>12 months) and short (<12 months)
duration of the complaints at baseline, in patients with a
low, moderate or high total activity score derived from
the SQUASH questionnaire (in tertiles), in patients re-
cruited in general practice and by sports physicians and
in patients where the podiatrist agrees with the indica-
tion for orthotic insoles and in patients where the podia-
trist does not.
Discussion
In order to explore the effectiveness of custom-made in-
soles, we will compare the insole to a placebo insole.
One earlier study found similar effects on pain and func-
tion at both short and long-term follow-up between pla-
cebo insoles and custom made podiatric insoles [18].
Since both groups showed improvement during follow-
up, the improvements seen in pain reduction might be
caused by either a real placebo effect or the natural
course of the condition. Therefore, we will also compare
custom made insoles with usual care.
It has also been acknowledged that the placebo effect
plays a role in clinical trials using orthotic devices and
that the development of a placebo intervention in these
trials is a difficult task [39]. For the current study pur-
pose we will design a custom placebo insole for each
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foot separately. As a consequence each subject in the
placebo insole group will be provided with an insole that
gives as little support as possible. The material and the
features of the custom-made insole cannot be identical
to the placebo insole, since this would interfere with its
function. However, we will make the placebo insole look
as similar to the orthotic insole as possible (in shape),
by producing placebo insoles tailored for each patient.
By doing this, the placebo insoles will have a 3D ef-
fect (but lower than the custom made insole), without
expecting therapeutic effects. By making both type of
insoles look as similar as possible, we hope to achieve
successful blinding of patients for the type of treat-
ment received. We will assess success of blinding of
patients by means of a single question in the 26 week
questionnaire.
We expect to find a larger difference between the cus-
tom made insole group and the usual care group, com-
pared to the custom made and placebo insole groups,
since patients allocated to the usual care group are likely
to have a different attitude towards their treatment. It is
worthwhile to study these differences since this provides
information on the treatment with custom made podiat-
ric insoles compared to other strategies used in daily
practice and on the possible placebo effect involved with
treatment with insoles. This knowledge will improve the
insight into the treatment of plantar fasciopathy as it is
currently given in clinical practice.
We will include patients from both general practice
and sport medicine clinics. Previous studies have sug-
gested possible subgroups of patients, which might be
represented by the two different recruitment settings.
For example, patients recruited in general practice are
more likely to be middle-aged with perhaps higher mean
BMI’s, whereas patients recruited by sports physicians
are probably more physically active compared to
those in general practice. By performing a stratified
randomization for type of referral we will be able to
analyze the possible difference in effectiveness of in-
soles in subgroup analysis.
Our sample size calculation is based on the data from
Landorf et al. [18] This trial is to tour knowledge the
only trial that has compared a custom made insole to a
sham insole. The pain score in this trial was derived
from the Foot Health Status Questionnaire, which is a
pain score with a scale from 0 to 100. The primary out-
come of the present study is pain severity measured on a
0–10 point NRS-scale. In order to determine our sample
size, we have rescaled the pain severity outcomes for
application on the 0–10 NRS.
The strength of this study is that we will perform a
trial in which we will compare custom made insoles, a
preferred treatment in patients with plantar fasciopathy,
to a placebo treatment and usual care. The results will
contribute to clinical decision making in primary health
care when it comes to plantar fasciopathy and will add-
itionally provide information on the cost-effectiveness of
podiatric care including orthotic insoles.
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